|
Characteristic
|
Placebo (n = 79)
|
ch-OSA (n = 87)
|
Male (n = 46)
|
Female (n = 120)
|
|---|
|
Age (years)
|
62.2 ± 7.7
|
61.7 ± 6.5
|
61.0 ± 7.2
|
62.3 ± 7.0
|
|
Women
|
55 (69.6)
|
65 (74.7)
|
0
|
120 (100)
|
|
Body mass index (kg/m2)
|
29.5 ± 5.2
|
29.5 ± 5.4
|
29.1 ± 4.7
|
29.6 ± 5.6
|
|
Menopausal Status
|
1 pre (1.5)
|
1 pre (1.8)
|
-
|
2 pre (1.7)
|
|
0 peri (1.5)
|
1 peri
|
1 peri (0.8)
|
|
54 post (98.2)
|
63 post (96.9)
|
117 post (97.5)
|
|
Kellgren and Lawrence grade II
|
48 (60.8)
|
59 (67.8)
|
26 (56.5)
|
81 (67.5)
|
|
Kellgren and Lawrence grade III
|
31 (39.2)
|
28 (32.2)
|
20 (43.5)
|
39 (32.5)
|
|
Likert pain score 2
|
38 (48.1)
|
32 (36.8)
|
19 (41.3)
|
51 (42.5)
|
|
Likert pain score 3
|
41 (51.9)
|
55 (63.2)
|
27 (58.7)
|
69 (57.5)
|
|
WOMAC Total (/100 mm)
|
43.1 ± 20.3
|
40.9 ± 19.4
|
42.2 ± 21.5
|
41.9 ± 19.2
|
|
WOMAC Pain (/100 mm)
|
41.2 ± 20.3
|
38.2 ± 19.8
|
41.9 ± 20.9
|
38.7 ± 19.7
|
|
WOMAC Stiffness (/100 mm)
|
45.3 ± 24.6
|
44.0 ± 23.5
|
44.9 ± 23.4
|
44.5 ± 24.3
|
|
WOMAC Function (/100 mm)
|
43.4 ± 21.2
|
41.4 ± 19.8
|
42.0 ± 22.5
|
42.5 ± 19.7
|
|
Subject Global Assessment (/100 mm)
|
49.4 ± 21.8
|
50.1 ± 18.2
|
51.3 ± 22.4
|
49.2 ± 19.0
|
|
CTX-II/Creatinine (ng/mmol)
|
413.1 ± 189.6
|
430.4 ± 212.7
|
378.5 ± 162.8
|
441.0 ± 213.9
|
|
COMP (U/L)
|
10.8 ± 2.8
|
10.7 ± 2.8
|
11.0 ± 2.8
|
10.6 ± 2.8
|
|
Estradiol (ng/L)
|
-
|
-
|
35.5 ± 31.0
|
22.0 ± 36.2 a
|
- Data expressed as mean ± SD or n (%);-: not applicable; a significant difference between groups (men versus women); Number of patients without outliers for CTX-II: Placebo (n = 66), ch-OSA (n = 68); Number of patients without outliers for COMP: Placebo (n = 74), ch-OSA (n = 80)
